Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cytomegalovirus phosphoprotein 65 (pp65) is a major structural and immunodominant protein of the human cytomegalovirus (HCMV). It is a tegument protein and one of the most abundantly produced proteins in HCMV virions. pp65 elicits strong CD4+ and CD8+ T cell responses in seropositive individuals. It is being explored as a target for adoptive T-cell therapies, especially in glioblastoma multiforme (GBM), where it serves as a tumor-specific antigen.
Induction of T-cell mediated cytotoxicity
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cytomegalovirus phosphoprotein 65 (CMV pp65).